Description
InformationBPTES BPTES is a potent and selective Glutaminase GLS1 (KGA) inhibitor with IC50 of 0.16 µM. It has no effect on glutamate dehydrogenase activity and causes only a very slight inhibition of γ-glutamyl transpeptidase activity.In vitroBPTES inhibits glutaminase activity expressed in human kidney cells with IC50 of 0.18 µM, and inhibits glutamate efflux by microglia with IC50 of 80-120 nM. BPTES preferentially slows cell growth in D54 cells with mutant IDH1. BPTES also inhibits glutaminase activity, lowers glutamate and α-KG levels, and increases glycolytic intermediates. BPTES (10 µM) inhibits cell growth of mHCC 3–4 cells derived from LAP/MYC tumors. BPTES also inhibits growth of a MYC-dependent P493 cells by blocking DNA replication, leading to cell death and fragmentation.In vivoIn LAP/MYC mice, BPTES (12.5 mg/kg, i.p.) prolongs survival with no significant effects on MYC, GLS, or GLS2 levels. BPTES (200 µg/mouse, i.p.) also inhibits tumor cell growth in mice harboring P493 tumor xenografts.Cell Datacell lines：CEM-SS cellsConcentrations：--Incubation Time：48 hPowder Purity: